LL-37

LL-37 is the body's only human cathelicidin — a 37-residue cationic, amphipathic α-helical peptide cleaved from the hCAP-18 precursor stored in neutrophil granules, keratinocytes, mast cells, and epithelial tissue. It's not a growth-signaling peptide like BPC-157 or TB-500; it's an innate immunity peptide that happens to also drive angiogenesis and re-epithelialization. Three distinct mechanisms run in parallel, which is why the use-cases span chronic infection, wound healing, and post-procedural recovery.

Direct Antimicrobial Membrane Disruption#

The cationic face of the helix binds anionic microbial surfaces — LPS on gram-negatives, lipoteichoic acid on gram-positives, ergosterol-rich fungal membranes, viral envelopes — then inserts into the bilayer to form pores and cause lysis. Unlike a targeted antibiotic, this is a physical mechanism that pathogens struggle to develop resistance against, and it works on biofilm-embedded organisms that conventional antibiotics can't reach. This is the rationale behind stacking LL-37 with standard antimicrobials in chronic infection protocols.

"LL-37 exhibited broad-spectrum antimicrobial activity, displaying lytic effects on more than 38 bacterial species, 16 fungi, and 16 viruses in vitro and in vivo models." — Fazli M. et al., Biochimica et Biophysica Acta, 2025

LPS Neutralization and Immunomodulation#

LL-37 binds and sequesters bacterial endotoxin before it can trigger a full cytokine cascade, suppresses macrophage pyroptosis (the inflammatory cell-death pathway that drives IL-1β release in sepsis), and triggers neutrophil extracellular trap (NET) formation — a mechanism where neutrophils eject DNA webs loaded with antimicrobial proteins to trap pathogens. The net effect is damping down the hyperinflammatory tail of infection while simultaneously increasing pathogen clearance.

"LL-37 attenuates the severity of sepsis by neutralizing LPS, reducing IL-1β release, and promoting neutrophil extracellular trap (NET) formation." — Aloul K.M. et al., International Journal of Molecular Sciences, 2020

Angiogenesis via FPR2 Signaling#

LL-37 binds formyl peptide receptor 2 (FPR2/FPRL1) on endothelial cells and upregulates VEGFa and IL-6, driving new capillary growth into wound beds. This is why topical and peri-wound administration outperforms distant SC injection for healing-focused protocols — angiogenesis is a local phenomenon, and LL-37's short half-life in serum means systemic dosing leaves less peptide at the target site than putting it there directly.

"LL37 exhibited accelerated wound closure associated with increased angiogenesis, collagen deposition, and granulation tissue formation in a full-thickness excisional wound model." — Chereddy K.K. et al., Journal of Controlled Release, 2014

Keratinocyte Migration and Re-epithelialization#

Through a P2X7 → EGFR → ADAM17 signaling axis, LL-37 drives keratinocyte migration and proliferation at the wound edge, accelerating closure of the epithelial barrier. Practically: LL-37 covers a different piece of the healing cascade than BPC-157 (tendon/fibroblast) or GHK-Cu (ECM remodeling), which is why the three stack cleanly for post-surgical and post-transplant recovery rather than compete.

"LL37 treatment resulted in enhanced keratinocyte migration and proliferation, promoting re-epithelialization and accelerating the wound closure process." — Ramos R. et al., Peptides, 2011

The Inflammatory Double-Edge (TLR2 / Mast Cells / Self-DNA)#

This is the mechanism that makes LL-37 different from every other healing peptide and dictates who should not run it. When LL-37 is overexpressed or abnormally processed by kallikrein-5 into shorter fragments, it activates TLR2/MyD88/NF-κB signaling and triggers mast cell degranulation — the core pathology of rosacea. It also binds self-DNA and self-RNA released from damaged cells, forming complexes that activate plasmacytoid dendritic cells via TLR9/TLR7, which is the initiating event in psoriasis.

"Aberrant expression and proteolytic processing of LL-37 contributes to the pathogenesis of rosacea by activating TLR2/MyD88/NF-κB signaling and mast cell degranulation." — Reinholz M., Ruzicka T., Schauber J., Annals of Dermatology, 2012

The takeaway: in a user with a healthy inflammatory set-point, LL-37 is a potent pro-resolution, pro-healing, anti-infection tool. In a user with rosacea, psoriasis, or active autoimmune disease, the same peptide amplifies the exact pathway driving their condition. Screen for this before the first injection — it's the one mechanism that decides whether this compound works for an individual or against them.

Common (most users)#

• Injection-site redness, stinging, or a small welt — LL-37 is a long cationic peptide and is locally irritating by nature. Reconstitute to a lower concentration (dilute the 5 mg vial in 3 mL instead of 2 mL if needed), push slowly, and rotate sites daily. Pinching up a proper SC fold and going shallow into abdominal fat tolerates better than thigh or flank.
• Transient flushing / facial warmth in the first 30–60 minutes post-injection. Dosing in the evening for the first week may align transient effects with sleep; usually subsides within 3–5 days of consistent dosing.
• Mild headache or "off" feeling the first 2–3 days, consistent with immune activation. Hydrate, keep the starting dose at 100 mcg, and ramp only once the first week settles.
• Low-grade fatigue in week 1 as cytokine signalling shifts. Does not persist — if it persists to day 7–10, the dose may be too high for individual tolerance; reduce to 100 mcg.

"LL37 exhibited accelerated wound closure associated with increased angiogenesis, collagen deposition, and granulation tissue formation in a full-thickness excisional wound model." — Chereddy et al., J Control Release (2014)

Uncommon (dose-dependent or individual)#

• Persistent injection-site inflammation that doesn't resolve between doses — a signal you're either dosing too frequently or reacting to the peptide itself. Back off to every other day, or stop and reassess at week 2.
• Facial erythema, telangiectasia-like flushing, or skin sensitivity that builds across weeks 2–4. This is the early rosacea-pathway signal and it means stop — do not push through it. LL-37 directly activates TLR2/MyD88/NF-κB and mast-cell degranulation in susceptible skin.
• Rising hs-CRP at the week-4 check. Most users running LL-37 for a real chronic-infection indication see CRP drop. If yours is climbing, the peptide is net pro-inflammatory for you — discontinue.
• GI upset / loose stools at advanced doses (300–500 mcg), usually from broad antimicrobial activity shifting gut flora. Drop back to 200 mcg or cycle off earlier than planned.
• Sleep disruption / vivid dreams in a subset of users, particularly when dosing in the evening. Shift to AM dosing.

"Aberrant expression and proteolytic processing of LL-37 contributes to the pathogenesis of rosacea by activating TLR2/MyD88/NF-κB signaling and mast cell degranulation." — Reinholz et al., Ann Dermatol (2012)

Rare but serious#

• Rosacea-like dermatitis — persistent facial erythema, papulopustular flare, burning sensation. Stop immediately and do not restart. This is not a "work through it" effect; animal models literally induce rosacea by injecting LL-37 intradermally.
• Psoriasis onset or flare in susceptible users. LL-37 binds self-DNA/RNA to form complexes that activate plasmacytoid dendritic cells via TLR9/TLR7 — one of the core mechanisms of psoriasis. New scaly plaques, scalp or elbow involvement, or nail changes = stop.
• Autoimmune symptom amplification — joint pain, new rashes, unexplained fatigue, or serological shifts in anyone with latent autoimmunity. Stop and get basic antibody work (ANA, RF, CRP) before considering any further peptide use.
• Allergic / hypersensitivity reaction — hives, bronchospasm, angioedema. Rare with SC peptides but possible with any cationic antimicrobial. Stop, antihistamine, seek care if airway involvement.
• Topical over-concentration burns — at >50 μg/mL in vitro, LL-37 becomes hemolytic and cytotoxic to mammalian cells. Keep topical preparations ≤0.5 mg/mL; do not "stack up" concentration hoping for more effect.

"LL-37 attenuates the severity of sepsis by neutralizing LPS, reducing IL-1β release, and promoting neutrophil extracellular trap (NET) formation." — Aloul et al., Int J Mol Sci (2020)

Hard contraindications#

• Rosacea, persistent facial erythema, or strong family history of rosacea — LL-37 is mechanistically causal in rosacea pathogenesis. Avoid systemic or topical administration on the face.
• Psoriasis or psoriasis-prone phenotype — LL-37/self-nucleic-acid complexes drive the pDC–TLR9 axis central to psoriasis. Off the table.
• Active autoimmune disease — lupus, psoriatic arthritis, dermatomyositis, or any condition driven by self-nucleic-acid recognition. LL-37 amplifies exactly that pathway.
• Pregnancy or lactation — safety not established, no data. Avoid.
• Known peptide hypersensitivity or prior anaphylactoid reaction to antimicrobial peptides.
• High-dose vitamin D (>10,000 IU/day) stacked without thought — vitamin D is the endogenous inducer of cathelicidin expression, and compounding endogenous production with exogenous LL-37 is a reasonable way to push a susceptible user into the rosacea/psoriasis pathway. Not absolute, but think twice.

Sex-specific and PCT considerations#

LL-37 is non-hormonal — no HPTA suppression, no androgenic or estrogenic activity, no virilization risk, no impact on menstrual cycle or semen parameters. No PCT required. Dosing is identical for men and women.

The one sex-skewed consideration worth naming: rosacea prevalence is higher in women, particularly fair-skinned women in their 30s–50s. That's the single population most likely to see a bad skin reaction on LL-37, and it's worth an honest mirror check before starting. If there's any background facial flushing, telangiectasia, or "sensitive skin" history, skip this peptide and reach for BPC-157, TB-500, or thymosin alpha-1 instead — all of which cover most of the same use cases without the rosacea-pathway risk.

Monitoring: baseline and week-4 hs-CRP is the single most useful marker. CBC with differential and a basic metabolic panel round it out. If CRP rises on cycle, stop — that's the peptide telling you it's net pro-inflammatory in your individual case, and no amount of dose adjustment fixes that signal.